1
|
Mito-TIPTP Increases Mitochondrial Function by Repressing the Rubicon-p22phox Interaction in Colitis-Induced Mice. Antioxidants (Basel) 2021; 10:antiox10121954. [PMID: 34943057 PMCID: PMC8750874 DOI: 10.3390/antiox10121954] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2021] [Revised: 11/29/2021] [Accepted: 12/03/2021] [Indexed: 12/25/2022] Open
Abstract
The run/cysteine-rich-domain-containing Beclin1-interacting autophagy protein (Rubicon) is essential for the regulation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase by interacting with p22phox to trigger the production of reactive oxygen species (ROS) in immune cells. In a previous study, we demonstrated that the interaction of Rubicon with p22phox increases cellular ROS levels. The correlation between Rubicon and mitochondrial ROS (mtROS) is poorly understood. Here, we report that Rubicon interacts with p22phox in the outer mitochondrial membrane in macrophages and patients with human ulcerative colitis. Upon lipopolysaccharide (LPS) activation, the binding of Rubicon to p22phox was elevated, and increased not only cellular ROS levels but also mtROS, with an impairment of mitochondrial complex III and mitochondrial biogenesis in macrophages. Furthermore, increased Rubicon decreases mitochondrial metabolic flux in macrophages. Mito-TIPTP, which is a p22phox inhibitor containing a mitochondrial translocation signal, enhances mitochondrial function by inhibiting the association between Rubicon and p22phox in LPS-primed bone-marrow-derived macrophages (BMDMs) treated with adenosine triphosphate (ATP) or dextran sulfate sodium (DSS). Remarkably, Mito-TIPTP exhibited a therapeutic effect by decreasing mtROS in DSS-induced acute or chronic colitis mouse models. Thus, our findings suggest that Mito-TIPTP is a potential therapeutic agent for colitis by inhibiting the interaction between Rubicon and p22phox to recover mitochondrial function.
Collapse
|
2
|
Martinez J, Cook DN. What's the deal with efferocytosis and asthma? Trends Immunol 2021; 42:904-919. [PMID: 34503911 PMCID: PMC9843639 DOI: 10.1016/j.it.2021.08.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2021] [Revised: 08/04/2021] [Accepted: 08/12/2021] [Indexed: 01/19/2023]
Abstract
Mucosal sites, such as the lung, serve as crucial, yet vulnerable barriers to environmental insults such as pathogens, allergens, and toxins. Often, these exposures induce massive infiltration and death of short-lived immune cells in the lung, and efficient clearance of these cells is important for preventing hyperinflammation and resolving immunopathology. Herein, we review recent advances in our understanding of efferocytosis, a process whereby phagocytes clear dead cells in a noninflammatory manner. We further discuss how efferocytosis impacts the onset and severity of asthma in humans and mammalian animal models of disease. Finally, we explore how recently identified genetic perturbations or biological pathway modulations affect pathogenesis and shed light on novel therapies aimed at treating or preventing asthma.
Collapse
Affiliation(s)
- Jennifer Martinez
- Immunity, Inflammation, and Disease Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA.
| | - Donald N Cook
- Immunity, Inflammation, and Disease Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA
| |
Collapse
|
3
|
Zhao Y, Pu M, Zhang J, Wang Y, Yan X, Yu L, He Z. Recent advancements of nanomaterial-based therapeutic strategies toward sepsis: bacterial eradication, anti-inflammation, and immunomodulation. NANOSCALE 2021; 13:10726-10747. [PMID: 34165483 DOI: 10.1039/d1nr02706a] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
Sepsis is a life threatening disease that is caused by a dysregulated host immune response to infection, resulting in tissue damage and organ dysfunction, which account for a high in-hospital mortality (approximately 20%). However, there are still no effective and specific therapeutics for clinical sepsis management. Nanomaterial-based strategies have emerged as promising tools for improving the therapeutic efficacy of sepsis by combating lethal bacterial infection, modulating systemic inflammatory response, preventing multiple organ failure, etc. This review has comprehensively summarized the recent advancements in nanomaterial-based strategies for the management of sepsis and severe complications, in which those nanosystems act either as inherent therapeutics or as nanocarriers for the precise delivery of agents. These formulations mechanically possess antibacterial, anti-inflammatory, immunomodulatory, and anti-oxidative effects, achieving multifunctional synergistic treatment efficacy against sepsis. Furthermore, several cell membrane-derived biomimetic nanoplatforms have been used as decoys to trap and neutralize the pathogenic toxins. The critical role of other adjuvant therapies in sepsis management, including the combination of nanotechnology and stem cell therapy, is also highlighted. Overall, this review provides insights into innovative nanotechnology-based strategies applied in sepsis treatment.
Collapse
Affiliation(s)
- Yi Zhao
- Key Laboratory of Marine Chemistry Theory and Technology, Ministry of Education, Ocean University of China, China.
| | - Minju Pu
- Key Laboratory of Marine Chemistry Theory and Technology, Ministry of Education, Ocean University of China, China.
| | - Jingwen Zhang
- Key Laboratory of Marine Chemistry Theory and Technology, Ministry of Education, Ocean University of China, China.
| | - Yanan Wang
- Key Laboratory of Marine Chemistry Theory and Technology, Ministry of Education, Ocean University of China, China.
| | - Xuefeng Yan
- Key Laboratory of Marine Chemistry Theory and Technology, Ministry of Education, Ocean University of China, China.
| | - Liangmin Yu
- Key Laboratory of Marine Chemistry Theory and Technology, Ministry of Education, Ocean University of China, China.
| | - Zhiyu He
- Key Laboratory of Marine Chemistry Theory and Technology, Ministry of Education, Ocean University of China, China.
| |
Collapse
|
4
|
Wan J, Weiss E, Ben Mkaddem S, Mabire M, Choinier PM, Picq O, Thibault-Sogorb T, Hegde P, Pishvaie D, Bens M, Broer L, Gilgenkrantz H, Moreau R, Saveanu L, Codogno P, Monteiro RC, Lotersztajn S. LC3-associated phagocytosis protects against inflammation and liver fibrosis via immunoreceptor inhibitory signaling. Sci Transl Med 2021; 12:12/539/eaaw8523. [PMID: 32295902 DOI: 10.1126/scitranslmed.aaw8523] [Citation(s) in RCA: 41] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2019] [Revised: 10/11/2019] [Accepted: 02/09/2020] [Indexed: 12/15/2022]
Abstract
Sustained hepatic and systemic inflammation, particularly originating from monocytes/macrophages, is a driving force for fibrosis progression to end-stage cirrhosis and underlies the development of multiorgan failure. Reprogramming monocyte/macrophage phenotype has emerged as a strategy to limit inflammation during chronic liver injury. Here, we report that LC3-associated phagocytosis (LAP), a noncanonical form of autophagy, protects against hepatic and systemic inflammation during chronic liver injury in rodents, with beneficial antifibrogenic effects. LAP is enhanced in blood and liver monocytes from patients with fibrosis and cirrhosis. Pharmacological inhibition of LAP components in human monocytes from patients with cirrhosis or genetic disruption of LAP in mice with chronic liver injury exacerbates both the inflammatory signature in isolated human monocytes and the hepatic inflammatory profile in mice, resulting in enhanced liver fibrosis. Mechanistically, patients with cirrhosis showed increased monocyte expression of Fc fragment of IgG receptor IIA (FcγRIIA) and enhanced engulfment of immunoglobulin G in LC3+ phagosomes that triggers an FcγRIIA/Src homology region 2 domain-containing phosphatase-1 (SHP-1) inhibitory immunoreceptor tyrosine-based activation motif (ITAMi) anti-inflammatory pathway. Mice overexpressing human FcγRIIA in myeloid cells show enhanced LAP in response to chronic liver injury and resistance to inflammation and liver fibrosis. Activation of LAP is lost in monocytes from patients with multiorgan failure and restored by specifically targeting ITAMi signaling with anti-FcγRIIA F(ab')2 fragments, or with intravenous immunoglobulin (IVIg). These data suggest the existence of an ITAMi-mediated mechanism by which LAP might protect against inflammation. Sustaining LAP may open therapeutic perspectives for patients with chronic liver disease.
Collapse
Affiliation(s)
- JingHong Wan
- Université de Paris, Centre de Recherche sur l'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, F-75018 Paris, France
| | - Emmanuel Weiss
- Université de Paris, Centre de Recherche sur l'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, F-75018 Paris, France.,Department of Anesthesiology and Critical Care, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, F-92110 Clichy, France
| | - Sanae Ben Mkaddem
- Université de Paris, Centre de Recherche sur l'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, F-75018 Paris, France
| | - Morgane Mabire
- Université de Paris, Centre de Recherche sur l'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, F-75018 Paris, France
| | - Pierre-Marie Choinier
- Université de Paris, Centre de Recherche sur l'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, F-75018 Paris, France.,Department of Anesthesiology and Critical Care, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, F-92110 Clichy, France
| | - Olivia Picq
- Université de Paris, Centre de Recherche sur l'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, F-75018 Paris, France.,Department of Anesthesiology and Critical Care, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, F-92110 Clichy, France
| | - Tristan Thibault-Sogorb
- Université de Paris, Centre de Recherche sur l'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, F-75018 Paris, France.,Department of Anesthesiology and Critical Care, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, F-92110 Clichy, France
| | - Pushpa Hegde
- Université de Paris, Centre de Recherche sur l'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, F-75018 Paris, France
| | - Dorsa Pishvaie
- Department of Hepatology, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, F-92110, Clichy, France
| | - Marcelle Bens
- Université de Paris, Centre de Recherche sur l'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, F-75018 Paris, France
| | - Linda Broer
- Université de Paris, Centre de Recherche sur l'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, F-75018 Paris, France
| | - Hélène Gilgenkrantz
- Université de Paris, Centre de Recherche sur l'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, F-75018 Paris, France
| | - Richard Moreau
- Université de Paris, Centre de Recherche sur l'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, F-75018 Paris, France.,Department of Hepatology, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, F-92110, Clichy, France
| | - Loredana Saveanu
- Université de Paris, Centre de Recherche sur l'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, F-75018 Paris, France
| | - Patrice Codogno
- Université de Paris Institut Necker-Enfants malades (INEM), INSERM, U1151, CNRS UMR8223, F-75015 Paris, France
| | - Renato C Monteiro
- Université de Paris, Centre de Recherche sur l'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, F-75018 Paris, France
| | - Sophie Lotersztajn
- Université de Paris, Centre de Recherche sur l'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, F-75018 Paris, France.
| |
Collapse
|
5
|
Kim JS, Cho E, Mun SJ, Kim S, Kim SY, Kim DG, Son W, Jeon HI, Kim HK, Jeong YJ, Jang S, Kim HS, Yang CS. Multi-Functional MPT Protein as a Therapeutic Agent against Mycobacterium tuberculosis. Biomedicines 2021; 9:biomedicines9050545. [PMID: 34068051 PMCID: PMC8152475 DOI: 10.3390/biomedicines9050545] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Revised: 05/03/2021] [Accepted: 05/12/2021] [Indexed: 02/07/2023] Open
Abstract
Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB), avoids the host immune system through its virulence factors. MPT63 and MPT64 are the virulence factors secreted by MTB which regulate host proteins for the survival and proliferation of MTB in the host. Here, we found that MPT63 bound directly with TBK1 and p47phox, whereas MPT64 interacted with TBK1 and HK2. We constructed a MPT63/64-derived multifunctional recombinant protein (rMPT) that was able to interact with TBK1, p47phox, or HK2. rMPT was shown to regulate IFN-β levels and increase inflammation and concentration of reactive oxygen species (ROS), while targeting macrophages and killing MTB, both in vitro and in vivo. Furthermore, the identification of the role of rMPT against MTB was achieved via vaccination in a mouse model. Taken together, we here present rMPT, which, by regulating important immune signaling systems, can be considered an effective vaccine or therapeutic agent against MTB.
Collapse
Affiliation(s)
- Jae-Sung Kim
- Department of Bionano Technology, Hanyang University, Seoul 04673, Korea; (J.-S.K.); (E.C.); (S.-J.M.); (S.-Y.K.)
- Institute of Natural Science & Technology, Hanyang University, Ansan 15588, Korea
| | - Euni Cho
- Department of Bionano Technology, Hanyang University, Seoul 04673, Korea; (J.-S.K.); (E.C.); (S.-J.M.); (S.-Y.K.)
- Center for Bionano Intelligence Education and Research, Ansan 15588, Korea; (W.S.); (H.-I.J.); (H.-K.K.); (Y.-J.J.); (S.J.)
| | - Seok-Jun Mun
- Department of Bionano Technology, Hanyang University, Seoul 04673, Korea; (J.-S.K.); (E.C.); (S.-J.M.); (S.-Y.K.)
- Center for Bionano Intelligence Education and Research, Ansan 15588, Korea; (W.S.); (H.-I.J.); (H.-K.K.); (Y.-J.J.); (S.J.)
| | - Sojin Kim
- Department of Molecular and Life Science, Hanyang University, Ansan 15588, Korea; (S.K.); (D.-G.K.)
| | - Sun-Young Kim
- Department of Bionano Technology, Hanyang University, Seoul 04673, Korea; (J.-S.K.); (E.C.); (S.-J.M.); (S.-Y.K.)
| | - Dong-Gyu Kim
- Department of Molecular and Life Science, Hanyang University, Ansan 15588, Korea; (S.K.); (D.-G.K.)
| | - Wooic Son
- Center for Bionano Intelligence Education and Research, Ansan 15588, Korea; (W.S.); (H.-I.J.); (H.-K.K.); (Y.-J.J.); (S.J.)
- Department of Molecular and Life Science, Hanyang University, Ansan 15588, Korea; (S.K.); (D.-G.K.)
| | - Hye-In Jeon
- Center for Bionano Intelligence Education and Research, Ansan 15588, Korea; (W.S.); (H.-I.J.); (H.-K.K.); (Y.-J.J.); (S.J.)
- Department of Molecular and Life Science, Hanyang University, Ansan 15588, Korea; (S.K.); (D.-G.K.)
| | - Hyo-Keun Kim
- Center for Bionano Intelligence Education and Research, Ansan 15588, Korea; (W.S.); (H.-I.J.); (H.-K.K.); (Y.-J.J.); (S.J.)
- Department of Molecular and Life Science, Hanyang University, Ansan 15588, Korea; (S.K.); (D.-G.K.)
| | - Young-Jin Jeong
- Center for Bionano Intelligence Education and Research, Ansan 15588, Korea; (W.S.); (H.-I.J.); (H.-K.K.); (Y.-J.J.); (S.J.)
- Department of Molecular and Life Science, Hanyang University, Ansan 15588, Korea; (S.K.); (D.-G.K.)
| | - Sein Jang
- Center for Bionano Intelligence Education and Research, Ansan 15588, Korea; (W.S.); (H.-I.J.); (H.-K.K.); (Y.-J.J.); (S.J.)
- Department of Molecular and Life Science, Hanyang University, Ansan 15588, Korea; (S.K.); (D.-G.K.)
| | - Hyun-Sung Kim
- Department of Pathology, Hanyang University College of Medicine, Seoul 04673, Korea;
| | - Chul-Su Yang
- Center for Bionano Intelligence Education and Research, Ansan 15588, Korea; (W.S.); (H.-I.J.); (H.-K.K.); (Y.-J.J.); (S.J.)
- Department of Molecular and Life Science, Hanyang University, Ansan 15588, Korea; (S.K.); (D.-G.K.)
- Correspondence: ; Tel.: +82-31-400-5519; Fax: +82-31-436-8153
| |
Collapse
|
6
|
Nah J, Zablocki D, Sadoshima J. The roles of the inhibitory autophagy regulator Rubicon in the heart: A new therapeutic target to prevent cardiac cell death. Exp Mol Med 2021; 53:528-536. [PMID: 33854187 PMCID: PMC8102471 DOI: 10.1038/s12276-021-00600-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2020] [Revised: 03/03/2021] [Accepted: 03/08/2021] [Indexed: 01/30/2023] Open
Abstract
Autophagy contributes to the maintenance of cardiac homeostasis. The level of autophagy is dynamically altered in heart disease. Although autophagy is a promising therapeutic target, only a few selective autophagy activator candidates have been reported thus far. Rubicon is one of the few endogenous negative regulators of autophagy and a potential target for autophagy-inducing therapeutics. Rubicon was initially identified as a component of the Class III PI3K complex, and it has multiple functions, not only in canonical autophagy but also in endosomal trafficking and inflammatory responses. This review summarizes the molecular action of Rubicon in canonical and noncanonical autophagy. We discuss the roles of Rubicon in cardiac stress and the therapeutic potential of Rubicon in cardiac diseases through its modulation of autophagy.
Collapse
Affiliation(s)
- Jihoon Nah
- Department of Cell Biology and Molecular Medicine, Cardiovascular Research Institute, Rutgers New Jersey Medical School, Newark, NJ, USA.
| | - Daniela Zablocki
- Department of Cell Biology and Molecular Medicine, Cardiovascular Research Institute, Rutgers New Jersey Medical School, Newark, NJ, USA
| | - Junichi Sadoshima
- Department of Cell Biology and Molecular Medicine, Cardiovascular Research Institute, Rutgers New Jersey Medical School, Newark, NJ, USA.
| |
Collapse
|
7
|
Kim SY, Kim D, Kim S, Lee D, Mun SJ, Cho E, Son W, Jang K, Yang CS. Mycobacterium tuberculosis Rv2626c-derived peptide as a therapeutic agent for sepsis. EMBO Mol Med 2020; 12:e12497. [PMID: 33258196 PMCID: PMC7721357 DOI: 10.15252/emmm.202012497] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2020] [Revised: 10/22/2020] [Accepted: 10/27/2020] [Indexed: 12/15/2022] Open
Abstract
The Rv2626c protein of Mycobacterium tuberculosis is a promising vaccine candidate owing to its strong serum antibody response in patients with tuberculosis. However, there is limited information regarding the intracellular response induced by Rv2626c in macrophages. In this study, we demonstrated that Rv2626c interacts with the RING domain of TRAF6 and inhibits lysine (K) 63‐linked polyubiquitination of TRAF6 (E3 ubiquitin ligase activity); this results in the suppression of TLR4 inflammatory signaling in macrophages. Furthermore, we showed that the C‐terminal 123–131‐amino acid Rv2626c motif promotes macrophage recruitment, phagocytosis, M2 macrophage polarization, and subsequent bacterial clearance. We developed rRv2626c‐CA, a conjugated peptide containing the C‐terminal 123–131‐amino acid Rv2626c that targets macrophages, penetrates the cell membrane, and has demonstrated significant therapeutic effects in a mouse model of cecal ligation and puncture‐induced sepsis. This multifunctional rRv2626c‐CA has considerably improved potency, with an IC50 that is 250‐fold (in vitro) or 1,000‐fold (in vivo) lower than that of rRv2626c‐WT. We provide evidence for new peptide‐based drugs with anti‐inflammatory and antibacterial properties for the treatment of sepsis.
Collapse
Affiliation(s)
- Sun Young Kim
- Department of Bionano Technology, Hanyang University, Seoul, South Korea
| | - Donggyu Kim
- Department of Molecular and Life Science, Hanyang University, Ansan, South Korea.,Center for Bionano Intelligence Education and Research, Hanyang University, Ansan, South Korea
| | - Sojin Kim
- Department of Molecular and Life Science, Hanyang University, Ansan, South Korea
| | - Daeun Lee
- Department of Molecular and Life Science, Hanyang University, Ansan, South Korea
| | - Seok-Jun Mun
- Department of Bionano Technology, Hanyang University, Seoul, South Korea.,Center for Bionano Intelligence Education and Research, Hanyang University, Ansan, South Korea
| | - Euni Cho
- Department of Bionano Technology, Hanyang University, Seoul, South Korea.,Center for Bionano Intelligence Education and Research, Hanyang University, Ansan, South Korea
| | - Wooic Son
- Department of Molecular and Life Science, Hanyang University, Ansan, South Korea.,Center for Bionano Intelligence Education and Research, Hanyang University, Ansan, South Korea
| | - Kiseok Jang
- Department of Pathology, Hanyang University College of Medicine, Seoul, South Korea
| | - Chul-Su Yang
- Department of Molecular and Life Science, Hanyang University, Ansan, South Korea.,Center for Bionano Intelligence Education and Research, Hanyang University, Ansan, South Korea
| |
Collapse
|
8
|
Toxoplasma gondii GRA9 Regulates the Activation of NLRP3 Inflammasome to Exert Anti-Septic Effects in Mice. Int J Mol Sci 2020; 21:ijms21228437. [PMID: 33182702 PMCID: PMC7696177 DOI: 10.3390/ijms21228437] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Revised: 11/05/2020] [Accepted: 11/06/2020] [Indexed: 02/06/2023] Open
Abstract
Dense granule proteins (GRAs) are essential components in Toxoplasma gondii, which are suggested to be promising serodiagnostic markers in toxoplasmosis. In this study, we investigated the function of GRA9 in host response and the associated regulatory mechanism, which were unknown. We found that GRA9 interacts with NLR family pyrin domain containing 3 (NLRP3) involved in inflammation by forming the NLRP3 inflammasome. The C-terminal of GRA9 (GRA9C) is essential for GRA9–NLRP3 interaction by disrupting the NLRP3 inflammasome through blocking the binding of apoptotic speck-containing (ASC)-NLRP3. Notably, Q200 of GRA9C is essential for the interaction of NLRP3 and blocking the conjugation of ASC. Recombinant GRA9C (rGRA9C) showed an anti-inflammatory effect and the elimination of bacteria by converting M1 to M2 macrophages. In vivo, rGRA9C increased the anti-inflammatory and bactericidal effects and subsequent anti-septic activity in CLP- and E. coli- or P. aeruginosa-induced sepsis model mice by increasing M2 polarization. Taken together, our findings defined a role of T. gondii GRA9 associated with NLRP3 in host macrophages, suggesting its potential as a new candidate therapeutic agent for sepsis.
Collapse
|
9
|
Yim D, Lee DE, So Y, Choi C, Son W, Jang K, Yang CS, Kim JH. Sustainable Nanosheet Antioxidants for Sepsis Therapy via Scavenging Intracellular Reactive Oxygen and Nitrogen Species. ACS NANO 2020; 14:10324-10336. [PMID: 32806029 DOI: 10.1021/acsnano.0c03807] [Citation(s) in RCA: 72] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
Abstract
Sepsis is an aberrant systemic inflammatory response mediated by excessive production of reactive oxygen species (ROS) and reactive nitrogen species (RNS). Developing an efficient antioxidant therapy for sepsis via scavenging ROS and RNS remains a big challenge owing to the insufficient activity and sustainability of conventional antioxidants. Herein, biocompatible transition-metal dichalcogenide antioxidants with excellent scavenging activity and sustainability for H2O2, O2•-, OH•, and nitric oxide are developed for effective sepsis treatment. WS2, MoSe2, and WSe2 nanosheets exfoliated and functionalized with a biocompatible polymer effectively scavenge mitochondrial and intracellular ROS and RNS in inflammatory cells. Among the nanosheets, WS2 most efficiently suppresses the excessive secretion of inflammatory cytokines along with scavenging ROS and RNS without affecting the expression levels of the anti-inflammatory cytokine and ROS-producing enzymes. The WS2 nanosheets significantly improve the survival rate up to 90% for severely septic mice by reducing systemic inflammation. The pharmacokinetics suggests that the WS2 nanosheets can be excreted from mice 3 days after intravenous injection. This work demonstrates the potential of therapeutic nanosheet antioxidants for effective treatment of ROS and RNS-related diseases.
Collapse
Affiliation(s)
- DaBin Yim
- Department of Chemical Engineering, Hanyang University, Ansan 15588, Republic of Korea
| | - Da-Eun Lee
- Department of Molecular and Life Science, Hanyang University, Ansan 15588, Republic of Korea
| | - Yoonhee So
- Department of Chemical Engineering, Hanyang University, Ansan 15588, Republic of Korea
| | - Chanhee Choi
- Department of Chemical Engineering, Hanyang University, Ansan 15588, Republic of Korea
| | - Wooic Son
- Department of Molecular and Life Science, Hanyang University, Ansan 15588, Republic of Korea
| | - Kiseok Jang
- Department of Pathology, Hanyang University College of Medicine, Seoul 04763, Republic of Korea
| | - Chul-Su Yang
- Department of Molecular and Life Science, Hanyang University, Ansan 15588, Republic of Korea
- Department of Bionano Technology, Hanyang University, Seoul 04763, Republic of Korea
| | - Jong-Ho Kim
- Department of Chemical Engineering, Hanyang University, Ansan 15588, Republic of Korea
| |
Collapse
|
10
|
Kim YR, Kim JS, Gu SJ, Jo S, Kim S, Young Kim S, Lee D, Jang K, Choo H, Kim TH, Jung JU, Min SJ, Yang CS. Identification of highly potent and selective inhibitor, TIPTP, of the p22phox-Rubicon axis as a therapeutic agent for rheumatoid arthritis. Sci Rep 2020; 10:4570. [PMID: 32165681 PMCID: PMC7067850 DOI: 10.1038/s41598-020-61630-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2019] [Accepted: 03/02/2020] [Indexed: 01/08/2023] Open
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease linked to oxidative stress, which is associated with significant morbidity. The NADPH oxidase complex (NOX) produces reactive oxygen species (ROS) that are among the key markers for determining RA’s pathophysiology. Therefore, understanding ROS-regulated molecular pathways and their interaction is necessary for developing novel therapeutic approaches for RA. Here, by combining mouse genetics and biochemistry with clinical tissue analysis, we reveal that in vivo Rubicon interacts with the p22phox subunit of NOX, which is necessary for increased ROS-mediated RA pathogenesis. Furthermore, we developed a series of new aryl propanamide derivatives consisting of tetrahydroindazole and thiadiazole as p22phox inhibitors and selected 2-(tetrahydroindazolyl)phenoxy-N-(thiadiazolyl)propanamide 2 (TIPTP, M.W. 437.44), which showed considerably improved potency, reaching an IC50 value up to 100-fold lower than an inhibitor that we previously synthesized reported N8 peptide-mimetic small molecule (blocking p22phox–Rubicon interaction). Notably, TIPTP treatment showed significant therapeutic effects a mouse model for RA. Furthermore, TIPTP had anti-inflammatory effects ex vivo in monocytes from healthy individuals and synovial fluid cells from RA patients. These findings may have clinical applications for the development of TIPTP as a small molecule inhibitor of the p22phox-Rubicon axis for the treatment of ROS-driven diseases such as RA.
Collapse
Affiliation(s)
- Ye-Ram Kim
- Department of Molecular & Life Science, Hanyang University, Ansan, 15588, South Korea.,Department of Bionano Technology, Hanyang University, Seoul, 04673, South Korea
| | - Jae-Sung Kim
- Department of Molecular & Life Science, Hanyang University, Ansan, 15588, South Korea.,Department of Bionano Technology, Hanyang University, Seoul, 04673, South Korea
| | - Su-Jin Gu
- Department of Chemical & Molecular Engineering/Applied Chemistry, Ansan, 15588, South Korea
| | - Sungsin Jo
- Hanyang University Hospital for Rheumatic Diseases, Seoul, 04763, South Korea
| | - Sojin Kim
- Department of Molecular & Life Science, Hanyang University, Ansan, 15588, South Korea
| | - Sun Young Kim
- Department of Molecular & Life Science, Hanyang University, Ansan, 15588, South Korea.,Department of Bionano Technology, Hanyang University, Seoul, 04673, South Korea
| | - Daeun Lee
- Department of Molecular & Life Science, Hanyang University, Ansan, 15588, South Korea
| | - Kiseok Jang
- Department of Pathology, Hanyang University College of Medicine, Seoul, 04763, South Korea
| | - Hyunah Choo
- Center for Neuro-Medicine, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, 02792, South Korea
| | - Tae-Hwan Kim
- Hanyang University Hospital for Rheumatic Diseases, Seoul, 04763, South Korea
| | - Jae U Jung
- Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90089, USA
| | - Sun-Joon Min
- Department of Chemical & Molecular Engineering/Applied Chemistry, Ansan, 15588, South Korea.
| | - Chul-Su Yang
- Department of Molecular & Life Science, Hanyang University, Ansan, 15588, South Korea. .,Department of Bionano Technology, Hanyang University, Seoul, 04673, South Korea.
| |
Collapse
|
11
|
Kim JS, Lee D, Kim D, Mun SJ, Cho E, Son W, Yang CS. Toxoplasma gondii GRA8-derived peptide immunotherapy improves tumor targeting of colorectal cancer. Oncotarget 2020; 11:62-73. [PMID: 32002124 PMCID: PMC6967779 DOI: 10.18632/oncotarget.27417] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2019] [Accepted: 12/19/2019] [Indexed: 12/20/2022] Open
Abstract
Targeted tumor and efficient, specific biological drug delivery in vivo has been one of the main challenges in protein-based cancer-targeted therapies. Mitochondria are potential therapeutic targets for various anti-cancer drugs. We have previously reported that protein kinase Cα-mediated phosphorylation of Toxoplasma gondii GRA8 is required for mitochondrial trafficking and regulating the interaction of the C-terminal of GRA8 with ATP5A1/SIRT3 in mitochondria. Furthermore, SIRT3 facilitates ATP5A1 deacetylation, mitochondrial activation, and subsequent antiseptic activity in vivo. Herein we developed a recombinant acidity-triggered rational membrane (ATRAM)-conjugated multifunctional GRA8 peptide (rATRAM-G8-M/AS) comprising ATRAM as the cancer-targeting cell-penetrating peptide, and essential/minimal residues for mitochondrial targeting or ATP5A1/SIRT3 binding. This peptide construct showed considerably improved potency about cancer cell death via mitochondria activity and biogenesis compared with rGRA8 alone in HCT116 human carcinoma cells, reaching an IC50 value of up to 200-fold lower in vitro and 500-fold lower in vivo. Notably, rATRAM-G8-M/AS treatment showed significant therapeutic effects in a mouse xenograft model through mitochondrial metabolic resuscitation, and it produced negligible immunogenicity and immune responses in vivo. Thus, these results demonstrate that rATRAM-G8-M/AS represents a useful therapeutic strategy against tumors, particularly colon cancer. This strategy represents an urgently needed paradigm shift for therapeutic intervention.
Collapse
Affiliation(s)
- Jae-Sung Kim
- Department of Molecular and Life Science, Hanyang University, Ansan 15588, S. Korea.,Department of Bionano Technology, Hanyang University, Seoul 04673, S. Korea
| | - Daeun Lee
- Department of Molecular and Life Science, Hanyang University, Ansan 15588, S. Korea
| | - Donggyu Kim
- Department of Molecular and Life Science, Hanyang University, Ansan 15588, S. Korea
| | - Seok-Jun Mun
- Department of Molecular and Life Science, Hanyang University, Ansan 15588, S. Korea.,Department of Bionano Technology, Hanyang University, Seoul 04673, S. Korea
| | - Euni Cho
- Department of Molecular and Life Science, Hanyang University, Ansan 15588, S. Korea.,Department of Bionano Technology, Hanyang University, Seoul 04673, S. Korea
| | - Wooic Son
- Department of Molecular and Life Science, Hanyang University, Ansan 15588, S. Korea
| | - Chul-Su Yang
- Department of Molecular and Life Science, Hanyang University, Ansan 15588, S. Korea.,Department of Bionano Technology, Hanyang University, Seoul 04673, S. Korea
| |
Collapse
|
12
|
Yin X, Xin H, Mao S, Wu G, Guo L. The Role of Autophagy in Sepsis: Protection and Injury to Organs. Front Physiol 2019; 10:1071. [PMID: 31507440 PMCID: PMC6716215 DOI: 10.3389/fphys.2019.01071] [Citation(s) in RCA: 54] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2019] [Accepted: 08/05/2019] [Indexed: 12/12/2022] Open
Abstract
Sepsis is a systemic inflammatory disease with infection, and autophagy has been shown to play an important role in sepsis. This review summarizes the main regulatory mechanisms of autophagy in sepsis and its latest research. Recent studies have shown that autophagy can regulate innate immune processes and acquired immune processes, and the regulation of autophagy in different immune cells is different. Mitophagy can select damaged mitochondria and remove it to deal with oxidative stress damage. The process of mitophagy is regulated by other factors. Non-coding RNA is also an important factor in the regulation of autophagy. In addition, more and more studies in recent years have shown that autophagy plays different roles in different organs. It tends to be protective in the lungs, heart, kidneys, and brain, and tends to be damaging in skeletal muscle. We also mentioned that some drugs can regulate autophagy. The process of modulating autophagy through drug intervention appears to be a new potential hope for the treatment of sepsis.
Collapse
Affiliation(s)
- Xin Yin
- Department of Critical Care Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China
| | - Huang Xin
- Department of Critical Care Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China
| | - Shuai Mao
- Department of Critical Care Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China
| | - Guangping Wu
- Department of Critical Care Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China
| | - Liheng Guo
- Department of Critical Care Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China
| |
Collapse
|
13
|
Jiang SJ, Tsai PI, Peng SY, Chang CC, Chung Y, Tsao HH, Huang HT, Chen SY, Hsu HJ. A potential peptide derived from cytokine receptors can bind proinflammatory cytokines as a therapeutic strategy for anti-inflammation. Sci Rep 2019; 9:2317. [PMID: 30783144 PMCID: PMC6381106 DOI: 10.1038/s41598-018-36492-z] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2017] [Accepted: 11/22/2018] [Indexed: 01/19/2023] Open
Abstract
Chronic inflammation is a pivotal event in the pathogenesis of cardiovascular diseases, including atherosclerosis, restenosis, and coronary artery disease. The efficacy of current treatment or preventive strategies for such inflammation is still inadequate. Thus, new anti-inflammatory strategies are needed. In this study, based on molecular docking and structural analysis, a potential peptide KCF18 with amphiphilic properties (positively charged and hydrophobic residues) derived from the receptors of proinflammatory cytokines was designed to inhibit cytokine-induced inflammatory response. Simulations suggested that KCF18 could bind to cytokines simultaneously, and electrostatic interactions were dominant. Surface plasmon resonance detection showed that KCF18 bound to both tumor necrosis factor-α (TNF-α) and interleukin-6, which is consistent with MM/PBSA binding free energy calculations. The cell experiments showed that KCF18 significantly reduced the binding of proinflammatory cytokines to their cognate receptors, suppressed TNF-α mRNA expression and monocyte binding and transmigration, and alleviated the infiltration of white blood cells in a peritonitis mouse model. The designed peptide KCF18 could remarkably diminish the risk of vascular inflammation by decreasing plasma cytokines release and by directly acting on the vascular endothelium. This study demonstrated that a combination of structure-based in silico design calculations, together with experimental measurements can be used to develop potential anti-inflammatory agents.
Collapse
Affiliation(s)
- Shinn-Jong Jiang
- Department of Biochemistry, School of Medicine, Tzu Chi University, Hualien, 97004, Taiwan
| | - Pei-I Tsai
- Department of Materials Science and Engineering, National Chiao-Tung University, Hsinchu, 30010, Taiwan
| | - Shih-Yi Peng
- Department of Biochemistry, School of Medicine, Tzu Chi University, Hualien, 97004, Taiwan
| | - Chun-Chun Chang
- Institute of Medical Sciences, Tzu Chi University, Hualien, 97004, Taiwan.,Department of Laboratory Medicine, Tzu Chi Medical Center, Hualien, 97004, Taiwan
| | - Yi Chung
- Department of Biochemistry, School of Medicine, Tzu Chi University, Hualien, 97004, Taiwan
| | - Hao-Hsiang Tsao
- Department of Biochemistry, School of Medicine, Tzu Chi University, Hualien, 97004, Taiwan
| | - Hsin-Ting Huang
- Department of Biochemistry, School of Medicine, Tzu Chi University, Hualien, 97004, Taiwan
| | - San-Yuan Chen
- Department of Materials Science and Engineering, National Chiao-Tung University, Hsinchu, 30010, Taiwan
| | - Hao-Jen Hsu
- Department of Biochemistry, School of Medicine, Tzu Chi University, Hualien, 97004, Taiwan. .,Department of Life Sciences, Tzu Chi University, Hualien, 97004, Taiwan.
| |
Collapse
|
14
|
Novel function of PiT1/SLC20A1 in LPS-related inflammation and wound healing. Sci Rep 2019; 9:1808. [PMID: 30755642 PMCID: PMC6372663 DOI: 10.1038/s41598-018-37551-1] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2018] [Accepted: 11/27/2018] [Indexed: 12/17/2022] Open
Abstract
PiT1/SLC20A1 is an inorganic phosphate transporter with additional functions including the regulation of TNFα-induced apoptosis, erythropoiesis, cell proliferation and insulin signaling. Recent data suggest a relationship between PiT1 and NF-κB-dependent inflammation: (i) Pit1 mRNA is up-regulated in the context of NF-κB pathway activation; (ii) NF-κB target gene transcription is decreased in PiT1-deficient conditions. This led us to investigate the role of PiT1 in lipopolysaccharide (LPS)-induced inflammation. MCP-1 and IL-6 concentrations were impaired in PiT1-deficient bone marrow derived macrophages (BMDMs) upon LPS stimulation. Lower MCP-1 and IL-6 serum levels were observed in Mx1-Cre; Pit1lox/lox mice dosed intraperitoneally with LPS. Lower PiT1 expression correlated with decreased in vitro wound healing and lower reactive oxygen species levels. Reduced IκB degradation and lower p65 nuclear translocation were observed in PiT1-deficient cells stimulated with LPS. Conversely, PiT1 expression was induced in vitro upon LPS stimulation. Addition of an NF-κB inhibitor abolished LPS-induced PiT1 expression. Furthermore, we showed that p65 expression activated Pit1 promoter activity. Finally, ChIP assays demonstrated that p65 directly binds to the mPit1 promoter in response to LPS. These data demonstrate a completely novel function of PiT1 in the response to LPS and provide mechanistic insights into the regulation of PiT1 expression by NF-κB.
Collapse
|
15
|
Li Q, Li L, Fei X, Zhang Y, Qi C, Hua S, Gong F, Fang M. Inhibition of autophagy with 3-methyladenine is protective in a lethal model of murine endotoxemia and polymicrobial sepsis. Innate Immun 2018; 24:231-239. [PMID: 29673286 PMCID: PMC6830927 DOI: 10.1177/1753425918771170] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Here, the regulatory role of autophagy is examined in both an LPS-induced lethal
endotoxic shock mouse model and cecal ligation and puncture (CLP) mouse model.
Autophagy-inhibitor 3-methyladenine (3-MA) and autophagy-enhancer rapamycin were
administrated to mice challenged with LPS or CLP. Animals challenged with LPS or
CLP combined with 3-MA displayed increased survival after endotoxemia, but LPS
combined with rapamycin worsened the endotoxic shock of the mice. Among the
different organs studied, the lungs and intestines exhibited significant
differences among LPS alone, LPS combined with 3-MA and LPS combined with
rapamycin. LPS combined with 3-MA attenuated the inflammatory damages of these
organs as compared with LPS alone. In contrast, LPS combined with rapamycin
increased damage in these organs. Consistently, serum inflammatory mediators
TNF-α and IL-6 were decreased by the treatment of LPS combined with 3-MA as
compared with LPS alone, while administration of LPS combined with rapamycin
increased the serum TNF-α and IL-6 levels. Similar results were found in mouse
bone marrow-derived macrophages exposed to LPS. Moreover, the regulatory effect
of autophagy to endotoxic shock is dependent on the TLR4 signaling pathway. Our
results demonstrate the central role of autophagy in the regulation of endotoxic
shock and its potential modulation for endotoxic shock treatment.
Collapse
Affiliation(s)
- Qirui Li
- Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, China
| | - Lingyun Li
- Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, China
| | - Xiaoyuan Fei
- Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, China
| | - Yuanyue Zhang
- Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, China
| | - Chang Qi
- Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, China
| | - Shuyao Hua
- Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, China
| | - Feili Gong
- Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, China
| | - Min Fang
- Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, China
| |
Collapse
|
16
|
Dong N, Wang Z, Chou S, Zhang L, Shan A, Jiang J. Antibacterial activities and molecular mechanism of amino-terminal fragments from pig nematode antimicrobial peptide CP-1. Chem Biol Drug Des 2018; 91:1017-1029. [PMID: 29266746 DOI: 10.1111/cbdd.13165] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2017] [Revised: 10/18/2017] [Accepted: 12/07/2017] [Indexed: 12/20/2022]
Abstract
High manufacturing costs and weak cell selectivity have limited the clinical application of naturally occurring peptides when faced with an outbreak of drug resistance. To overcome these limitations, a set of antimicrobial peptides was synthesized with the general sequence of (WL)n, where n = 1, 2, 3, and WL was truncated from the N-terminus of Cecropin P1 without initial serine residues. The antimicrobial peptide WL3 exhibited stronger antimicrobial activity against both Gram-negative and Gram-positive microbes than the parental peptide CP-1. WL3 showed no hemolysis even at the highest test concentrations compared to the parental peptide CP-1. The condition sensitivity assays (salts, serum, and trypsin) demonstrated that WL3 had high stability in vitro. Fluorescence spectroscopy and electron microscopy indicated that WL3 killed microbes by means of penetrating the membrane and causing cell lysis. In a mouse model, WL3 was able to significantly reduce the bacteria load in major organs and cytokines (TNF-α, IL-6, and IL-1β) levels in serum. In summary, these findings suggest that WL3, which was modified from a natural antimicrobial peptide, has enormous potential for application as a novel antibacterial agent.
Collapse
Affiliation(s)
- Na Dong
- The Laboratory of Molecular Nutrition and Immunity, Institute of Animal Nutrition, Northeast Agricultural University, Harbin, China
| | - Zhihua Wang
- The Laboratory of Molecular Nutrition and Immunity, Institute of Animal Nutrition, Northeast Agricultural University, Harbin, China
| | - Shuli Chou
- The Laboratory of Molecular Nutrition and Immunity, Institute of Animal Nutrition, Northeast Agricultural University, Harbin, China
| | - Licong Zhang
- The Laboratory of Molecular Nutrition and Immunity, Institute of Animal Nutrition, Northeast Agricultural University, Harbin, China
| | - Anshan Shan
- The Laboratory of Molecular Nutrition and Immunity, Institute of Animal Nutrition, Northeast Agricultural University, Harbin, China
| | - Junguang Jiang
- The State Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, China
| |
Collapse
|
17
|
Shi KL, Qian JY, Qi L, Mao DB, Chen Y, Zhu Y, Guo XG. Atorvastatin antagonizes the visfatin-induced expression of inflammatory mediators via the upregulation of NF-κB activation in HCAECs. Oncol Lett 2016; 12:1438-1444. [PMID: 27446449 PMCID: PMC4950623 DOI: 10.3892/ol.2016.4796] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2014] [Accepted: 06/07/2016] [Indexed: 12/30/2022] Open
Abstract
The present study investigated whether atorvastatin antagonizes the visfatin-induced expression of inflammatory mediators in human coronary artery endothelial cells (HCAECs). Several analysis methods, such as reverse transcription-quantitative polymerase chain reaction, western blot analysis and H2DCFDA incubation, were used in the present study. The data showed that atorvastatin decreased the visfatin-induced expression of interleukin (IL)-6 and IL-8 in HCAECs. In addition, atorvastatin inhibited the visfatin-induced expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in HCAECs. In addition, the present study found that atorvastatin inhibited the visfatin-activated nuclear factor-κB (NF-κB) signal pathway by preventing extracellular signal-regulated kinase phosphorylation in HCAECs. Atorvastatin significantly inhibited visfatin-induced NF-κB activity via the upregulation of reactive oxygen species production. Atorvastatin, a visfatin antagonist (FK866) and an NF-κB inhibitor (BAY11-7082) decreased the visfatin-induced expression of inflammatory mediators via the upregulation of NF-κB activation in HCAECs. These results suggest that atorvastatin may inhibit the visfatin-induced upregulation of inflammatory mediators through blocking the NF-κB signal pathway. The findings of the present study provide a potential use for atorvastatin and visfatin in the pathogenesis of HCAEC dysfunction. This knowledge may contribute to the development of novel therapies for atherosclerosis.
Collapse
Affiliation(s)
- Kai-Lei Shi
- Department of Cardiology, Huadong Hospital Affiliated to Fudan University, Shanghai 200040, P.R. China
| | - Ju-Ying Qian
- Department of Cardiology, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China
| | - Lin Qi
- Department of Radiology, Huadong Hospital Affiliated to Fudan Universtiy, Shanghai 200040, P.R. China
| | - Ding-Biao Mao
- Department of Radiology, Huadong Hospital Affiliated to Fudan Universtiy, Shanghai 200040, P.R. China
| | - Yang Chen
- Department of Cardiology, Huadong Hospital Affiliated to Fudan University, Shanghai 200040, P.R. China
| | - Yi Zhu
- Department of Cardiology, Huadong Hospital Affiliated to Fudan University, Shanghai 200040, P.R. China
| | - Xin-Gui Guo
- Department of Cardiology, Huadong Hospital Affiliated to Fudan University, Shanghai 200040, P.R. China
| |
Collapse
|